FDA-cleared profile

Quantitative Total Extensible Imaging (QTxI)

AIQ Solutions, Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: QTxI manages and evaluates supported DICOM CT and PET studies, including registration, fusion, region-of-interest contouring, quantitative analysis, and evaluation of quantitative changes in the labeled workflow.

Clinical role
Medical image management, visualization, registration, fusion, measurement, or quantitative PET and nuclear-medicine analysis.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Multi-region
Key limitation
Keep in mind: Tracer, modality, image quality, registration, quantitative method, anatomy, and downstream workflow limits are release-specific. QTxI manages and evaluates supported DICOM CT and PET studies, including registration, fusion, region-of-interest contouring, quantitative analysis, and evaluation of quantitative changes in the labeled workflow.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: QTxI manages and evaluates supported DICOM CT and PET studies, including registration, fusion, region-of-interest contouring, quantitative analysis, and evaluation of quantitative changes in the labeled workflow.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Multi-region Input: Supported DICOM PET or nuclear-medicine studies with the CT or MR data and metadata required by the exact workflow.
  • Who uses it?Intended users: Qualified radiologists, nuclear medicine physicians, technologists, and trained imaging professionals.
  • What does the software produce?Output: Processed image series, registrations, measurements, quantitative values, and reports for professional review.
  • What is its most important limitation?Key limitation: Tracer, modality, image quality, registration, quantitative method, anatomy, and downstream workflow limits are release-specific. QTxI manages and evaluates supported DICOM CT and PET studies, including registration, fusion, region-of-interest contouring, quantitative analysis, and evaluation of quantitative changes in the labeled workflow.

Clinical takeaway. Clinical role: QTxI manages and evaluates supported DICOM CT and PET studies, including registration, fusion, region-of-interest contouring, quantitative analysis, and evaluation of quantitative changes in the labeled workflow.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical performance bench tests and simulated clinical performance tests to verify device characteristics, including software verification testing that the device meets product performance and functional specifications and that DICOM information is captured, transmitted, and stored properly to maintain data integrity; it states the device met all predetermined acceptance criteria of design verification and validation. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
QTxI manages and evaluates supported DICOM CT and PET studies, including registration, fusion, region-of-interest contouring, quantitative analysis, and evaluation of quantitative changes in the labeled workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Medical image management, visualization, registration, fusion, measurement, or quantitative PET and nuclear-medicine analysis.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported DICOM PET or nuclear-medicine studies with the CT or MR data and metadata required by the exact workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Processed image series, registrations, measurements, quantitative values, and reports for professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
PET, nuclear-medicine, oncology, cardiology, or radiotherapy-planning workstations using supported DICOM studies.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiologists, nuclear medicine physicians, technologists, and trained imaging professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Tracer, modality, image quality, registration, quantitative method, anatomy, and downstream workflow limits are release-specific. QTxI manages and evaluates supported DICOM CT and PET studies, including registration, fusion, region-of-interest contouring, quantitative analysis, and evaluation of quantitative changes in the labeled workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical performance bench tests and simulated clinical performance tests to verify device characteristics, including software verification testing that the device meets product performance and functional specifications and that DICOM information is captured, transmitted, and stored properly to maintain data integrity; it states the device met all predetermined acceptance criteria of design verification and validation. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical performance bench tests and simulated clinical performance tests have been performed on the Quantitative Total Extensible Imaging (QTxI) in order to verify the device characteristics." … "Software verification testing that demonstrates the device meets product performance and functional specifications.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical performance bench tests and simulated clinical performance tests to verify device characteristics, including software verification testing that the device meets product performance and functional specifications and that DICOM information is captured, transmitted, and stored properly to maintain data integrity; it states the device met all predetermined acceptance criteria of design verification and validation. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical performance bench tests and simulated clinical performance tests have been performed on the Quantitative Total Extensible Imaging (QTxI) in order to verify the device characteristics." … "Software verification testing that demonstrates the device meets product performance and functional specifications.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K173444

  • DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K173444.
  • PopulationThe labeled population and test materials for exact submission K173444; a general clinical study population is not established here.
  • Scopeexact submission
  • Tested versionQuantitative Total Extensible Imaging (QTxI) (K173444)
  • IndependenceSponsor or vendor study

K173444

FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.

1 unlinked candidate evidence record is retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported DICOM PET or nuclear-medicine studies with the CT or MR data and metadata required by the exact workflow.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA decision summary for K173444 - Quantitative Total Extensible Imaging (QTxI)

  2. Routing

    Source context, not route validation: The exact FDA package describes QTxI functioning as a PACS that receives, stores, retrieves, displays and processes digital medical images, with DICOM CT and PET as supported by ACR/NEMA DICOM 3.0. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "QTxI also functions as a Picture Archive and Communications System (PACS) intended to receive, store, retrieve, display and process digital medical images" … "The medical modalities of these medical images include DICOM CT and PET as supported by ACR/NEMA DICOM 3.0.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA decision summary for K173444 - Quantitative Total Extensible Imaging (QTxI)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Processed image series, registrations, measurements, quantitative values, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA decision summary for K173444 - Quantitative Total Extensible Imaging (QTxI)

  5. Viewer/worklist/report

    Unresolved route: Processed image series, registrations, measurements, quantitative values, and reports for professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA decision summary for K173444 - Quantitative Total Extensible Imaging (QTxI)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact FDA package describes QTxI functioning as a PACS that receives, stores, retrieves, displays and processes digital medical images, with DICOM CT and PET as supported by ACR/NEMA DICOM 3.0. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "QTxI also functions as a Picture Archive and Communications System (PACS) intended to receive, store, retrieve, display and process digital medical images" … "The medical modalities of these medical images include DICOM CT and PET as supported by ACR/NEMA DICOM 3.0.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Training
The 510(k) summary states QTxI is a software tool used to aid in evaluation and information management of digital medical images by trained medical professionals including, but not limited to, radiologists, oncologists, nuclear medicine physicians, medical imaging technologists, dosimetrists and physicists.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Workflow role

Medical image management, visualization, registration, fusion, measurement, or quantitative PET and nuclear-medicine analysis.

exact submission · checked 2026-09-04

This is a submission-anchored intended-use summary, not a local acceptance result.

Input

Supported DICOM PET or nuclear-medicine studies with the CT or MR data and metadata required by the exact workflow.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Processed image series, registrations, measurements, quantitative values, and reports for professional review.

exact submission · checked 2026-09-04

Output review, editing, and downstream use remain release- and site-specific.

Vendor family context

Current vendor material is product-family context for K173444 only; exact release, enabled options, deployment, and local interoperability require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Site validation status

Exact local interfaces, deployment topology, security controls, downtime behavior, and support obligations remain unestablished.

exact submission · checked 2026-09-04

Obtain organization-specific implementation evidence before procurement or clinical use.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K173444
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-07-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not applicable - checked 2026-09-04 - Not applicable

    CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA decision summary for K173444 - Quantitative Total Extensible Imaging (QTxI)

    U.S. Food and Drug Administration - Published 2018-07-23 - Accessed 2026-09-04

    Scope: regulatoryIdentity, productIdentity, indication, modality, anatomy, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Quantitative Total Extensible Imaging (QTxI) model card (K173444)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. AIQ Solutions QTxI family context

    AIQ Solutions - Accessed 2026-09-04

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  9. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

Research history

  1. K173444 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253270

Contour ProtégéAI+

Mim Software, Inc.

Authorized purpose: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252539

Tempus Pixel

Arterys, Inc.

Authorized purpose: Multimodality DICOM image management, quantitative analysis, optional cardiovascular MR mapping and flow analysis, and therapy-response lesion tracking for trained clinicians.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-09-03
FDA-cleared K243647

Synapse PACS (7.5)

FUJIFILM Healthcare Americas Corporation

Authorized purpose: Synapse PACS version 7.5 provides primary processing and presentation of DICOM and supported non-DICOM images with measurement, segmentation, fusion, volume rendering, reporting, integrated 3D, two-point VOI, and AI-assisted bone removal.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-06-30
FDA-cleared K243933

Ceevra Reveal 3+

Ceevra, Inc.

Authorized purpose: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-03-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history